

1 **Title Page**

2

3 **Title:**

4 The international trial of nasal oxygen therapy after cardiac surgery (NOTACS) in patients at high risk of
5 postoperative pulmonary complications: Economic evaluation protocol and analysis plan

6

7 **Short title:**

8 Economic evaluation protocol for NOTACS trial

9

10 **Authors and affiliations:**

11 **Siddesh Shetty¹, Melissa Duckworth², Richard Norman³, Jacquita Affandi^{3,4}, Sarah Dawson^{2,5}, Julia Fox-**
12 **Rushby^{1, *}, On behalf of NOTACS investigators⁶, On behalf of NOTACS Trial Steering Committee⁶, On**
13 **behalf of NOTACS DMEC Committee⁶**

14

15 ¹ School of Life Course and Population Sciences, King's College London, United Kingdom

16 ² Papworth Trials Unit Collaboration, Royal Papworth Hospital NHS Foundation Trust, Cambridge, United
17 Kingdom

18 ³ Curtin School of Population Health, Curtin University, Perth, Western Australia

19 ⁴ Fiona Stanley Hospital, Perth, Western Australia

20 ⁵ MRC Biostatistics Unit, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom

21 ⁶ Membership of the NOTACS investigators, NOTACS Trial Steering Committee and NOTACS DMEC
22 Committee is provided in the supplementary S2 appendix

23 * Corresponding author

24 E-mail: julia.fox-rushby@kcl.ac.uk (JF)

25

26 **Abstract:**

27

28 Introduction

29 High-Flow Nasal Therapy (HFNT) is an innovative non-invasive form of respiratory support. Compared to
30 standard oxygen therapy (SOT), there is an equipoise regarding the effect of HFNT on patient-centred
31 outcomes among those at high risk of developing postoperative pulmonary complications after
32 undergoing cardiac surgery. The NOTACS trial aims to determine the clinical and cost-effectiveness of
33 HFNT compared to SOT within 90 days of surgery in the United Kingdom, Australia, and New Zealand. This
34 protocol describes the methods and analyses planned for economic evaluation embedded within the
35 ongoing NOTACS trial.

36

37 Methods and analysis

38 The economic evaluation will identify, measure and value resources and health outcomes in both trial
39 arms and compare changes in costs with 'days alive and at home' and EQ-5D-5L quality adjusted life years
40 (QALYs) from the perspective most relevant to the decision-making country. Results from pooling data
41 across the trial will use health and social care sector perspective. All patient-specific data including

42 hospital/community care and health outcomes will be collected prospectively. Unit costs will be sourced
43 from national, published or local data. Missing data will be assessed, with values replaced depending on
44 assumed mechanism of missingness, and impact of replacement on cost-effectiveness assessed. Costs and
45 outcomes by trial arm will be presented as components and totals per patient using a range of descriptive
46 statistics. Regression models for costs and effects will account for patient characteristics, quality of life
47 and health service utilization at baseline. Uncertainty in parameters, sampling and heterogeneity will be
48 addressed through deterministic, probabilistic and subgroup analyses to assess the impact of varying
49 methods and assumptions for costs, outcomes and approaches used in base-case analysis. Results will be
50 interpreted using recommended national cost-effectiveness thresholds.

51

52 Registration details

53 The study is registered with ISRCTN (ISRCTN14092678) on 13/05/2020. ISRCTN is a primary registry of
54 the WHO ICTRP network and includes all items from the WHO Trial Registration data set.

55

56

57

58

59

60

61

62

63 Introduction:

64 United Kingdom (UK), Australia (AUS), and New Zealand (NZ) reported a total of 42,456 cardiac surgical
65 procedures in 2022-23 (1,2). Patients undergoing cardiac surgery are at risk of developing postoperative
66 pulmonary complications (PPC), leading to prolonged hospitalisation and an increase in healthcare costs
67 (3,4). The risk is further exacerbated in patients having intrinsic respiratory disease and lower airway
68 obstruction, obese patients, and heavy smokers (5). The peri-extubation period is crucial in managing such
69 high-risk patients. These patients more often require prolonged ventilatory support and readmission
70 during recovery (6,7).

71

72 High-Flow Nasal Therapy (HFNT) is an innovative non-invasive form of respiratory support that has
73 increasingly gained attention as a bridge between low flow oxygen and continuous positive airway
74 pressure (CPAP) (8). HFNT has physiological benefits and is better tolerated by patients compared to other
75 techniques of non-invasive ventilation (NIV) and conventional oxygen therapy (9). Recent systematic
76 reviews have ascertained the efficacy and safety of HFNT in adult post-operative patients by
77 demonstrating a reduction in length of hospital stay and the need for respiratory support (10,11). There
78 is however an equipoise regarding the use of HFNT in patients at high risk of developing PPC undergoing
79 cardiac surgery.

80

81 The NOTACS trial is an adaptive, multi-centre, multi-country, parallel group, randomised controlled trial
82 (RCT) with embedded economic evaluation. The trial compares the use of HFNT versus SOT in patients at
83 high risk of developing PPC after undergoing cardiac surgery. The trial has two primary aims; to determine
84 whether prophylactic use of HFNT for a minimum of 16 hours after tracheal extubation increases days

85 alive and at home (DAH) at 90 days after surgery, and to estimate the incremental cost-effectiveness and
86 cost-utility of HFNT versus SOT at 90 days after surgery.

87

88 There is very little evidence available on the cost-effectiveness of HFNT. A decision model from England
89 found HFNT to be cost saving in ICU patients but indicated limitations with clinical effectiveness and
90 costing methods (12). Similarly, a US-based model found HFNT to be cost-effective in COPD patients on
91 long-term oxygen but is based on findings from a single-centre trial that used outcomes from a different
92 healthcare setting (13). The limited available economic evidence is mostly based on decision models,
93 heterogenous population subgroups, different settings that have limitations for input costs, consequences
94 or are funded by manufacturers (12–16). Therefore, the actual cost-effectiveness of HFNT in adult patients
95 at high risk of developing PPC undergoing cardiac surgery is currently unknown.

96

97 The economic evaluation alongside NOTACS is designed to provide the first international economic
98 evidence on the use of HFNT for adults at high risk of developing PPC undergoing cardiac surgery. The
99 primary objective is to assess the cost-effectiveness (i.e. incremental cost per gain in ‘days alive and at
100 home’ at 90 days after surgery (DAH90)) and cost-utility (i.e. incremental cost per Quality Adjusted Life
101 Years (QALY) gained) for HFNT versus SOT comparison from the health and social care sector perspective.
102 The secondary objectives include addition of patient/family perspective and estimation of cost-
103 effectiveness at 30 days after surgery. This protocol paper (Version 1.0, 23rd September 2024) describes
104 the methods and analyses planned for this economic evaluation.

105

106 **Methods and analysis:**

107

108 **Study design**

109 The NOTACS trial protocol (Trial registration ID: ISRCTN14092678) and statistical analysis plan are
110 published elsewhere following the SPIRIT recommendations (Fig 1 & Table S1; S1 Appendix) (17–19). The
111 trial examines patient centred outcomes for HFNT versus SOT comparison by using a single-blind strategy
112 that assigns eligible patients randomly in a 1:1 allocation ratio, until a sample size of 1280 cases is achieved
113 by recruiting participants from 10 sites in the UK, 7 in AUS and 1 in NZ. The trial population includes adult
114 patients undergoing elective or urgent first-time or redo cardiac surgery performed on cardiopulmonary
115 bypass, having one or more clinical risk factors for PPC. Randomisation is performed after surgery
116 initiation and patients are followed up for 90 days after surgery.

117 Fig 1. Outlines study components in accordance with SPIRIT guidelines

118 (EuroSCORE II: European System for Cardiac Operative Risk Evaluation, ARISCAT risk assessment: Assess
119 Respiratory Risk in Surgical Patients in Catalonia, EQ-5D-5L: EuroQol 5-Dimensions 5-Levels, ROX index:
120 Ratio of Oxygen Saturation to FiO₂ and Respiratory Rate)

121 **Intervention and control arms**

122 After cardiac surgery, patients are transferred to intensive care units (ICU). Once a patient fulfils the local
123 hospital criteria for extubation, they are extubated as per the trial extubation protocol (17). Those
124 randomised to the intervention arm receive HFNT for a minimum of 16 hours with up to one hour off
125 treatment allowed for hospital moves or physiotherapy mobilisation. Following the extubation protocol,
126 patients allocated HFNT are started off on 40% fraction of inspired oxygen (FiO₂) and a flow of 30 litres
127 per minute (L/min) then up to 50 L/min over 5 to 10 minutes. Patients are monitored and clinically

128 assessed at least every 24 hours to either discontinue, continue, or escalate respiratory support as
129 recommended by the trial protocol (17).

130

131 Patients assigned to control arm follow the exact same pathway except for a difference in the mode of
132 oxygen therapy delivery following extubation. Patients receive SOT via nasal prongs or non-rebreathing
133 masks (not humidified and not heated) as is currently practiced. Patients on SOT are started on 30–40%
134 inspired oxygen at a flow of 2 to 6 L/min, monitored and assessed as recommended (17).

135

136 **Within trial economic evaluation**

137 The economic analysis is designed to inform decisions in the UK, AUS, and NZ. Given the difference
138 between these health systems, the perspective most relevant to decision-making country will be chosen
139 first for analysis. This includes the National Health Service (NHS) and Personal Social Services (PSS)
140 perspective in the UK, the health care system (Medicare/Australian Government Department of Social
141 Services, including costs accruing both in public and private hospitals) perspective in AUS and the health
142 sector and individual perspective in NZ (20–22). A trial wide pooled cost-effectiveness results, if
143 determined following analyses, will use a health and social care sector perspective. The time horizon for
144 the analysis is 90 days post-surgery.

145

146 Data collection takes place at five main time points; baseline (surgery admission), randomisation (during
147 or after surgery, prior to extubation), on day of discharge, and on days 30 (+30-day follow-up window)
148 and 90 (+90-day follow-up window) following surgery. The first patient was recruited on 7/10/2020, the
149 last patient recruited on 19/06/2024 and final follow-up is expected to be completed by 16/12/2024.
150 Some data is also collected between time points, for example inpatient location and patient location diary

151 during follow-up. Data collection records patient outcomes, resources and services utilised from both the
152 health/social care sector and patient/family perspective. Data collection tools were designed in the UK
153 following inputs from the trial team, patients, their carers, and members of the public. The tools were
154 adapted for use in AUS with advice from the trial team and patient public representatives and in NZ with
155 advice from the trial team. The data collection tools use country specific questions or response categories
156 where necessary and accounts for good practice and methods guidance (20,23).

157

158 **Costing: identification, measurement, and valuation of resources**

159 **a) Identification of resource use**

160 Resource use relates to setting up and delivery of HFNT (including the HFNT device, level of use, associated
161 oxygen consumption, training, and maintenance) or SOT (oxygen flow rate, delivery using nasal mask or
162 prong) and its consequences i.e. use of hospital, primary, community and social care until 90 days after
163 surgery for both trial arms. Resource use from the individual/family perspective include expenses for
164 medical, non-medical and social care support services, and time spent by patients and caregivers following
165 randomisation. Table 1 provides a summary of all resources and services identified and collected alongside
166 the trial. As an incremental approach is used in costing, resources common to both arms and those related
167 to conducting the research are excluded.

168

169 **b) Measurement of resource use**

170 Health and social care resources are collected using a variety of patient-specific case report forms (CRFs).
171 Some are completed by research nurses abstracting data from patient-specific records (e.g. oxygen
172 therapy, in-patient location, discharge details), some through research nurses interviewing patients face-
173 to-face or using online, telephone or paper questions as preferred (e.g. quality of life, costs over hospital

174 stay, service use and expenditure post-surgery). Participant location and medication diary following
 175 discharge is the only record directly filled in by the patients. Relevant resources used to provide the service
 176 but not limited to specific patients (for example, HFNT training, equipment and maintenance) are
 177 measured using research records if available. The source and level of resource use measurements taken
 178 are provided in Table 1.

179

180 Table 1. Identification and measurement of costs

| Resource Use | Description of resources used | Unit of measure | Source, level data collected |
|--|--|--|---|
| Health & social care sector perspective | | | |
| HFNT intervention setup | - HFNT device - Training - Maintenance | - Unit cost - Number of trainings - Unit cost | - Published/local sources - Project records - Published/local sources |
| Initial admission | | | |
| HFNT | - Amount of oxygen used - Consumables | - FiO2, flow rate - Duration | - CRF, patient specific - Published manual |
| SOT | - Amount of oxygen used - Consumables | - Flow rate - Duration | - CRF, patient specific - Clinical expert opinion |
| Other ventilation support | - CPAP, mechanical ventilation, etc. | - Duration | - CRF, patient specific |

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

| | | | |
|---|---|--------------------|------------------------------------|
| Inpatient admission, by ward | - Admission to wards, high dependency unit, intensive care unit, etc. | - Duration | - CRF, patient specific |
| Complications after surgery | - Return to operation theatre after initial surgery | - Frequency | - CRF, patient specific |
| Medications | - All medications during admission | - Number of drugs | - CRF, patient specific |
| Diagnostics | - Blood tests, x-ray, ECG, CT scan, microbiology, etc. | - Number of tests | - CRF, patient specific |
| Health professional visits | - Physiotherapy, occupational therapy, social worker, etc. | - Number of visits | - CRF, patient specific |
| Transport - Ambulance use | - Travel to hospital | - Number of visits | - CRF, patient specific |
| <i>Discharge to day 90 after initial surgery</i> | | | |
| Transport - Ambulance use | - Travel to hospital | - Number of visits | - CRF, patient specific |
| Hospital admission | - Overnight admission to hospital, nursing home | - Number of visits | - CRF/GP records, patient specific |

| | | | |
|---|---|--------------------------------|-------------------------|
| Medications | - All medications from discharge to day 90 | - Number of drugs | - CRF, patient specific |
| Diagnostics | - Blood tests, x-ray, etc. | - Number of tests | - CRF, patient specific |
| Day hospital services | - Outpatient clinics, physiotherapy, accident & emergency, etc. | - Number of visits | - CRF, patient specific |
| GP surgery services | - GP surgery to see a doctor, nurse, other professionals | - Number of visits | - CRF, patient specific |
| Home visits/ telephone consultation | - Home visit from health or social care professionals | - Number of visits | - CRF, patient specific |
| | - Telephone consultation | - Number of consultations | |
| Social support services | - Care worker, overnight care, meals on wheels, etc. | - Number of contacts | - CRF, patient specific |
| Patient/family perspective | | | |
| <i>Initial admission</i> | | | |
| Admission | - Contribution/payment during initial surgery admission | - Patient reported cost | - CRF, patient specific |
| Transport | - Travel to and from hospital for surgery. | - Patient reported travel time | - CRF, patient specific |
| | | | - CRF, patient specific |

| | | | |
|---|---|-------------------------|--|
| | - Visitor travel | | |
| Miscellaneous | - Food, drink, accommodation expense | - Patient reported cost | - CRF, patient specific |
| Time lost to illness | - Main activity done by patient if not in surgery. For example, paid work, unpaid work, caring etc. | - Time lost | - CRF, patient specific |
| Accompanying person time spent in caring | - Main activity done by accompanying person if not caring | - Time spent | - CRF, patient specific |
| <i>Discharge to day 90 after initial surgery</i> | | | |
| Admission | - Contribution/payment for nursing home, residential care, etc. | - Patient reported cost | - CRF, patient specific |
| Diagnostics | - Contribution/payment for blood tests, x-ray, etc. | - Patient reported cost | - CRF, patient specific |
| Social support services | - Contribution/payment for home help, night care, meals on wheels, etc. | - Patient reported cost | - CRF, patient specific |
| Medical supplies and equipment | - Medical supplies: For example, prescriptions, aspirin, compression socks, nebulizer, etc. | - Patient reported cost | - CRF, patient specific - CRF, patient specific |

| | | | |
|--|--|--------------------------------|-------------------------|
| | - Equipment: For example, walking aids, special bedding, etc. | - Patient reported cost | |
| Transport | - Travel to hospital, GP surgery, etc. | - Patient reported travel time | - CRF, patient specific |
| Home adaptation | - Adaptation made to home. For example, ramp, stair-lift, etc. | - Patient reported cost | - CRF, patient specific |
| Time lost to illness | - Care arrangements, time off work, etc. | - Patient reported time | - CRF, patient specific |
| Accompanying person time spent in caring | - Main activity done by accompanying person if not caring | - Time spent | - CRF, patient specific |

181 (HFNT – High Flow Nasal Therapy, FiO₂ - fraction of inspired oxygen, CRF – Case Report Form, SOT – Standard Oxygen therapy,
 182 CPAP - Continuous positive airway pressure, ECG - Electrocardiogram, CT-Scan - Computed Tomography Scan, GP - General
 183 practitioner)

184

185 The amount of oxygen used with HFNT and SOT forms a relevant differential resource between the trial
 186 arms and hence is costed. As the central oxygen supply is common to both HFNT and SOT, the analysis
 187 measures only the variation in amount of oxygen supplied either by HFNT or SOT at a patient-specific
 188 level. For SOT, the CRF records oxygen flow rate titration in L/min and duration of use to give total quantity
 189 of oxygen used. For HFNT, the CRF records FiO₂ and the gas flow rate (L/min). Using an indicative chart,
 190 patient-specific data on FiO₂ and gas flow rate will be used to determine amount of oxygen used by HFNT
 191 (24). Consumables (e.g., oxygen interface, tubing, nasal prong) will be quantified using patient-specific

192 duration of oxygen therapy along with available duration of use guidance given by manufacturer or using
193 clinical expert opinion (25).

194

195 The changes to the data collection instruments in AUS and NZ included contextual country-specific
196 questions, responses and wording revisions for resource use data collection. This mainly included
197 replacing country-specific questions on ethnicity, education, healthcare concession and out-of-pocket
198 payments for ambulance travel, health professional visit and telephone consultations in AUS and NZ.
199 Additionally, during the trial, amendments were made to data collection tools to improve data
200 completion. Further details on data collection amendments are available in supplementary Table S2 (S1
201 Appendix).

202

203 c) Valuation of resource use

204 All health and social sector resources will be valued using national costs (for example, national cost
205 collection in the UK) for the latest available year (26–32). Any unit cost not in the corresponding year will
206 be adjusted using a health- or country-specific inflation index (for example, NHS cost inflation index
207 published in Personal Social Services Research Unit (PSSRU) cost manual) (31,33–36). If national unit costs
208 are unavailable, published literature or local cost sources will be used. Capital costs will be annualised
209 using country-specific discounting recommendations (3.5% UK, 5% AUS, 3.5% NZ) or using the 3.5% UK
210 recommendation for pooled results, further assessed in sensitivity analysis (20,21,37). For example, in
211 base-case, the HFNT device will be annualised using an average lifespan of 5 years, 3.5% discount rate and
212 an annualised maintenance cost using available sources. Patient reported expenses will be used to value
213 patient perspective costs. Time ‘spent’ by patients and caregivers will be valued using the human capital
214 approach based on gross national average wages (38–40). Unpaid work will be valued using wage earned
215 for similar work on a paid basis or using national average earnings if unavailable.

216
217
218
219
220
221
222
223
224
225
226

d) Computation of total costs

Total cost will be computed at a patient level by summing the components contributing to the cost of intervention delivery, initial admission and up to 90 days post-surgery relevant to health/social care sector and patient/family perspectives. For example, in base-case, per patient cost of HFNT arm in UK will include NHS/PSS perspective costs for HFNT delivery, initial admission and service utilisation until end of follow-up respectively. Total costs will be obtained by multiplying the quantity of resource use by unit cost across each subcomponent and then summing across. Some costs (for example, HFNT device) are expected to be shared between patients. In such cases, annualization, life-span and apportioning rules (for example, number of patients using the device) will be used as appropriate.

227 Outcomes: Identification, measurement, and valuation of health 228 outcomes

229 a) Identification of patient reported outcomes

230 Days alive and at home after surgery (DAH90), a validated patient-reported metric, is the primary outcome
231 endpoint for NOTACS trial (41). DAH90/DAH30 define home as a person's usual abode at 90 (and 30) days
232 post-surgery. Escalation of care or time away from usual abode during follow-up period will be counted
233 as a day away from home as per defined protocol. DAH is sensitive to changes in surgical risk and is
234 considered a superior measure of quality of surgery and care than standard complication and mortality
235 rates (42,43). The CRF records changes in the participant's overnight living location throughout follow-up.
236 It includes details on whether stay was planned and if support for daily living activities was needed. The
237 DAH measure will be used in cost-effectiveness analysis (CEA) as it was identified as the most important
238 primary outcome by patient and public representatives during development of the proposal.
239

240 For cost-utility analysis (CUA), a standardised generic health related quality of life measure, the EQ-5D-5L,
241 relevant to the UK, AUS, and NZ is used (20–22,44). The EQ-5D-5L consists of two parts; the first asks
242 respondents to categorise their health today on five dimensions (mobility, self-care, usual activities,
243 pain/discomfort, anxiety/depression) and five response levels (no problems, slight problems, moderate
244 problems, severe problems, unable to) for each dimension, and the second part asks respondents to rate
245 perception of their own overall health today on a scale of 0 (worst) to 100 (best) imaginable health.

246

247 **b) Measurement and valuation of patient reported outcomes.**

248 DAH90 and DAH30 are collected using a mix of CRFs completed by patients and research nurses from date
249 of index surgery to 90 days after surgery. Patients are given the location diary on discharge and have the
250 option of completing follow-up questionnaires on paper, online or via telephone. Patients not completing
251 follow-up CRFs at 30 and 90 days are contacted regularly up to 30+30 and 90+90 days as per trial protocol.
252 Information may be gathered from the patient’s general practitioner (GP) surgery in case of non-response
253 or to verify patient responses as per consent.

254

255 DAH90/DAH30 valuation accounts for any increase in care level from patient’s previous residence. For
256 example, hospital readmission or additional care requirement at ‘home’ within 90 days of surgery is
257 subtracted from the total number of days at home. Staying away from ‘home’ for social reasons without
258 any additional care or support is considered as home. The protocol for what counts as days away from
259 home is predefined and available in the update of the published statistical analysis plan (submitted and
260 under review). The location is based on where a patient spends the night. Patient records reporting
261 baseline or follow-up abode as ‘Other’ will be reviewed for whether the ‘other’ should be classed as
262 ‘home’ and agreed on a case-by-case basis by at least two blinded members. An additional blinded

263 member will be consulted if consensus is not reached. If a patient living at home is discharged from the
264 hospital on day 6 after surgery but is subsequently readmitted for 4 days and then returns home until 90
265 days post-surgery, they would be assigned 80 DAH90.

266

267 The base case statistical analysis for the trial follows the approach used by Myles et al., to count days at
268 home i.e. when a patient dies - a DAH value of 0 occurs for the whole period (18,41). For example, if a
269 patient dies while still in the hospital or at home before 90 days, they are assigned 0 DAH90. This means
270 no value is attributed whether a person lives for 1 or 89 days within the study period and no change can
271 be seen if survival changes over time. The trial is not designed to capture change in survival and one
272 reasoning to accept such a scoring is that it takes a more conservative view of benefit. However, for the
273 economic evaluation there are two problems in using this approach. First there is evidence that costs and
274 outcomes can be related and higher costs are particularly related to proximity to death (45–47). Through
275 an increase in outliers, and potential miscasting of the relationship between costs and effects, assigning a
276 zero value to all people dying could significantly bias regression results for cost-effectiveness. Second the
277 cost-utility analysis, part of the suite of tools in economic evaluation used to support NICE’s decision-
278 making, does account for all days lived. Therefore, the base-case cost-effectiveness analysis will be
279 conducted using all recorded days at home and dubbed ‘DAH90(HE)’ to represent a difference with
280 calculation of the main trial outcome DAH90, which will be used in sensitivity analysis, to allow comparison
281 with the main trial analysis.

282

283 Responses recorded on the EQ-5D-5L tool will be converted into a health state utility score using UK, AUS
284 and NZ specific value sets (48–50). As recommended in the UK, the EQ-5D-5L data will be mapped onto
285 the 3L value set (48,51), with QALYs calculated using the area under curve method (52). The study design

286 offers patients a tolerance window of 90 days for 90-day follow-up (and 30+30 days) to complete data
287 collection. Because utility values may be expected to rise over time post-surgery, sensitivity analysis will
288 explore the impact of using linear interpolations to obtain utility values at 90 days (53).

289

290 Analysis

291

292 a) Handling missing data

293 Before commencing analysis, data quality checks will be conducted and any duplicates, missing or extreme
294 values will be identified and documented. Any missing data will be cross-checked against the CRF and,
295 where necessary, patient records reviewed for procedural error. Clear outliers, such as those exceeding 4
296 standard deviations, will be investigated further and may be excluded or treated as missing values.
297 However, if a series of potential outliers appears within a skewed distribution, they may be retained. In
298 such cases, the data may be transformed (e.g., logarithmic or square root transformation) if necessary
299 and assessed in sensitivity analysis.

300

301 The pattern and amount of missing data at each time point will be summarised using frequency and
302 percentage plots, with pattern of missingness for resource use and outcomes assessed using Pearson Chi2
303 goodness of fit and Wilcoxon rank-sum tests at each data collection point (54). If data are missing
304 completely at random (MCAR) and the percentage of missing data is below 5%, a complete case analysis
305 (CCA) will be undertaken. This is unlikely to be the case due to the need to aggregate resource use and
306 costs across many variables. Data missing at random (MAR) will be addressed using multiple imputation
307 (MI) methods. Missing cost and outcome data will be estimated using joint chained equations with
308 predictive mean matching, stratified by treatment arm and country. We will explore censoring as a special

309 case of missing data, particularly right censoring from loss to follow-up to judge the impact on estimating
310 mean values for costs, DAH90 and QALYs using an inverse probability weighting approach (54). Imputation
311 models will be determined during analysis as it is important that the model includes variables that are
312 good predictors of missing variables. We will consider variables such as age, sex, baseline Barthel and/or
313 EQ-5D-5L scores, baseline health service use, BMI, ethnicity, number of co-morbidities, whether surgery
314 is elective, Euro Score II, ASA, and ARISCAT score. The number of imputed datasets required to achieve a
315 stable imputation will be used (55). The distribution of imputed and observed values will be compared
316 across both trial arms. Rubin's rule will be used to generate a complete single data set for analysis,
317 encompassing the variation and uncertainty preserved in the multiple imputed data sets (56). Sensitivity
318 analysis will assess the impact of different missingness assumptions (56). Total costs, DAH90(HE), utility
319 index score at day 90 and total QALYs with CCA, pre-imputed and imputed dataset will be presented for
320 HFNT versus SOT comparison.

321

322 **b) Statistical analysis of differences in resource use, costs, and outcomes for**
323 **cost-effectiveness and cost-utility analyses**

324 The intention-to-treat principle will be followed for base-case analyses. Resource use, costs and outcomes
325 will be summarised by trial arm; a) at discharge, 30- and 90-days, and b) by country at 90-days using
326 descriptive statistics (frequency, mean (standard deviation), median, minimum (including % of zeros),
327 maximum, IQR, 95% confidence interval around the mean, histograms and box plots) along with tests of
328 normality. Significant differences at 5% level, using raw and imputed data, will be tested using two-sample
329 t-tests of equality for normally distributed variables, and the Mann-Whitney-Wilcoxon test and
330 bootstrapped t-tests if skewed. This analysis will be repeated for a complete case analysis if feasible.
331 Changes in the EQ-5D-5L health profile will be summarised using the Paretian Classification of Health

332 Change and by reporting the ten most frequently observed health states at baseline and day 90 for both
333 trial arms (57). A Health Profile Grid will be developed for visual representation (57).

334

335 Regression models will be fitted for mean costs and QALYs, with and without imputed values. Models will
336 include intervention arm and variables to adjust for baseline patient characteristics (age, sex, Barthel, EQ-
337 5D score, health service use, BMI, ethnicity, number of co-morbidities and whether surgery is elective,
338 Euro Score II risk score, ASA and ARISCAT score). We will however be unable to control for baseline
339 differences such as patient/family borne costs. We will examine data prior to selecting a regression model
340 but will consider generalised linear or mixed models given their ability to handle large numbers of zeros
341 and will test log-link and more flexible forms to examine goodness of fit. We will assess the relationship
342 between baseline covariates for collinearity in the decision for covariate inclusion in the final model. We
343 will also examine the impact of accounting for the correlation between costs and QALYs, by using
344 seemingly unrelated regression analysis with and without correcting for confounding at baseline (58).

345

346 The difference in costs between the trial arms will be divided by the difference in outcomes between the
347 trial arms, to give incremental cost-effectiveness/utility ratios. Incremental cost-utility ratios (ICURs) will
348 be compared with country-specific costs-effectiveness thresholds (CET) used in the UK (£20,000/QALY),
349 AUS (AU\$ 28,033/QALY) and NZ (NZ\$ 40,000/QALY) (20,45,46). Fully pooled results will be reported in the
350 UK currency (country-specific unit cost applied to resource use followed by summing of all costs to UK
351 currency using purchasing power parity (PPP)) and assessed against the CET value for UK. Country-specific
352 incremental net monetary benefit (NMB) statistics, (INMB = incremental benefit * CET – incremental cost)
353 will be presented with 95% CI limits. As no CETs are available for DAH outcome, the incremental cost-
354 effectiveness ratios (ICERs) will be used to support wider decision making for any clearly dominant or

355 dominated strategies. We will follow the recommended framework to present cost-effectiveness and
 356 cost-utility estimates for this multinational trial (61,62) and present following; a) country-specific ICUR
 357 estimates using country-specific data on cost and QALY respectively b) country-specific ICUR estimates
 358 using trial-wide resource use valued against country-specific unit costs and trial-wide EQ-5D responses
 359 valued against domain level EQ-5D value set for chosen country) and, depending on evidence of
 360 heterogeneity, c) pooled trial-wide ICUR estimate by applying country-specific unit costs to resource use
 361 followed by summing costs to the common UK currency using PPP and summing country-specific QALYs
 362 using country-specific value sets into a pooled QALY value. The Likelihood ratio test and range test of
 363 qualitative interaction will be used to examine if the direction of cost-effectiveness varies between the
 364 countries (63,64). The likelihood ratio and standardised range test statistic will be compared against
 365 respective critical values at a significance level of $\alpha = 0.05$ for the three groups to indicate heterogeneity
 366 (63,65). We will explore the use of shrinkage estimates as an alternative to trial-wide pooling of cost-
 367 effectiveness results (66). Table 2 provides the methods and perspective considered in presenting the
 368 range of cost-effectiveness results.

369

370 Table 2. Methods and perspective for presenting the cost-effectiveness results for multinational NOTACS
 371 trial.

| Analysis | Primary (perspective) | Method | Secondary (perspective) | Method |
|----------------------------|----------------------------------|-----------------------|------------------------------------|-----------------------|
| a) Country specific | | | | |
| UK | NHS and PSS | Only UK specific data | NHS and PSS | Only UK specific data |

| | | | | |
|---|---|--|--|--|
| | | | + Individual (OOPE) + value of time use | |
| AUS | Health care system (includes public/private) | Only AUS specific data | Health care system (includes public/private) + value of time use | Only AUS specific data |
| NZ | Health sector + Individual (OOPE) | Only NZ specific data | Health sector + Individual (OOPE) + value of time use | Only NZ specific data |
| b) Country specific - trial pooled | | | | |
| UK | NHS and PSS | Resource use – UK, AUS, NZ combined Unit costs – UK Outcomes – UK, AUS, NZ combined and valued using UK tariff | NHS and PSS + Individual (OOPE) + value of time use | Resource use – UK, AUS, NZ combined Unit costs – UK Outcomes – UK, AUS, NZ combined and valued using UK tariff |
| AUS | Health care system (includes public/private) | Resource use – UK, AUS, NZ combined Unit costs – AUS | Health care system (includes public/private) + value of time use | Resource use – UK, AUS, NZ combined Unit costs – AUS |

| | | | | |
|------------------------|--|---|--|---|
| | | Outcomes – UK, AUS, NZ combined and valued using AUS tariff | | Outcomes – UK, AUS, NZ combined and valued using AUS tariff |
| NZ | Health sector + Individual (OOPE) | Resource use – UK, AUS, NZ combined Unit costs – NZ Outcomes – UK, AUS, NZ combined and valued using NZ tariff | Health sector + Individual (OOPE) + value of time use | Resource use – UK, AUS, NZ combined Unit costs – NZ Outcomes – UK, AUS, NZ combined and valued using NZ tariff |
| c) Fully pooled | | | | |
| Trial | Health and social care sector | Resource use – UK, AUS, NZ Unit costs – UK, AUS, NZ Total cost – UK, AUS, NZ combined to UK currency using PPP Outcomes – UK, AUS, NZ tariffs used on respective data for single combined QALY measure | Health and social care + Individual (OOPE) + value of time use | Resource use – UK, AUS, NZ Unit costs – UK, AUS, NZ Total cost – UK, AUS, NZ combined to UK currency using PPP Outcomes – UK, AUS, NZ tariffs used on respective data for single combined QALY measure |

372 (PPP – Purchasing power parity, NHS and PSS – National Health Services and Personal and Social Services, OOPE – Out-of-pocket
373 expenditure, AUS – Australia, NZ – New Zealand, UK – United Kingdom)

374

375 c) Handling uncertainty

376 Parameter uncertainty will be handled using one-way sensitivity analysis (OWSA) and scenario analysis to
377 assess the impact of following changes:

378 i) Costs

- 379 • HFNT intervention setup costs, including assumptions about length of life, device use and price.
- 380 • Oxygen therapy cost, any variation in oxygen consumption calculation.
- 381 • Any significant assumption in measurement or valuation methods for costs, including outliers (for
382 example, methods for follow-up/intravenous medication data collection, discount rate, etc).
- 383 • Cost at 30 days.
- 384 • Perspective (impact of including patient/family costs)

385

386 ii) Outcomes

- 387 • DAH90 to assess the impact of assigning a DAH value of zero for those dying between zero to 90
388 days post-surgery.
- 389 • Using linear interpolate and 90+90th day value as a proxy for 90th day utility value in QALY
390 calculation.
- 391 • Outcomes at 30 days.

392

393

394 Sampling uncertainty will be characterised using 95% CI limits for ICUR/ICER values based on non-
395 parametric bootstrapping along with cost-effectiveness plane (CEP) and cost-effectiveness acceptability
396 curves (CEAC) to inform decisions (20).

397

398 Heterogeneity will be assessed using sub-group analysis to improve robustness of our findings. The
399 potential subgroups to be explored are:

- 400 • Patients requiring escalation of oxygen therapy.
- 401 • Time on treatment (at least 8 or 24 hours)

402

403 Discussion

404 The NOTACS trial is the first international evidence comparing HFNT versus SOT in adult patients at high
405 risk of developing PPC undergoing cardiac surgery. The trial addresses clinical and economic evidence gaps
406 regarding the use of HFNT (10,11). A recent pilot study in this same population subgroup saw a reduction
407 in length of hospital stay by 29% and re-admission to ICU dropped from 14% to 2% with HFNT compared
408 to SOT (67). HFNT can potentially lead to significant cost-savings and offer good value for investment. The
409 NOTACS trial aims to inform policy recommendations in the UK, AUS, and NZ.

410

411 Strengths

412 This study has several strengths. First, this is the first study to measure and account for the cost of oxygen
413 therapy with HFNT or SOT following cardiac surgery using prospective, patient-level data. Second, the
414 analysis takes a multinational approach, incorporating methods and guidance relevant to decision-making
415 in three diverse healthcare systems. Our analysis aims at maximising the balance between using available
416 data from the trial with the perspective and methods most relevant to each country. Third, data collection

417 was influenced by inputs from patients and the public, is country-specific, and records both patient and
418 family costs, and time loss at a patient-level. This yields a potentially valuable source of evidence for
419 broader understanding of the economic implications of HFNT intervention. Fourth, the range of estimates
420 planned for, along with a wide range of sensitivity analyses will give a good indication of the robustness
421 of findings. Finally, the findings can indicate resource utilisation patterns and health benefits in other sub-
422 populations (e.g. following abdominal surgery) where HFNT can be used.

423

424 Limitations

425 There are limitations to the planned analyses. Firstly, in presenting the pooled cost-effectiveness results,
426 the study adopts a health and social care sector perspective. This includes the costs of community-based
427 services and home or continuing care, as recommended in the UK, AUS and NZ (20,68,69). However, this
428 pooled analysis will not include patient perspective costs, which form an important consideration in AUS
429 and NZ. This exclusion may limit the applicability of the pooled trial wide results to these countries. The
430 decision on perspective for pooled analysis was made because the trial was initially designed for, and
431 predominantly recruits from the UK. The analysis however does account for patient perspective costs
432 across all three countries and the cost-utility findings are presented ranging from country-specific to
433 pooled trial wide results, presenting relevant economic evidence for decisions. Secondly, the cost-
434 effectiveness analysis findings using DAH outcome measure relies on participation diaries completed by
435 patients to record any changes in location. Despite efforts to follow-up with patients' GP practice for
436 incomplete records, there still may be instances where this information is unavailable, potentially
437 influencing the cost-effectiveness findings. Thirdly, the analysis focuses on the cost-effectiveness of HFNT
438 for patients included in controlled trial settings which may differ from the broader population or more
439 real-world clinical settings. Finally, results are limited to 90 days of follow up and cost-effectiveness over
440 a longer period may differ.

441

442 Ethics and dissemination:

443 The study received ethics approval in the United Kingdom from Yorkshire & The Humber- Leeds West
444 Research Ethics Committee, Newcastle upon Tyne, UK on 2nd April 2020 (REC ref: 20/YH/0133). In
445 Australia, the approval was obtained from South Metropolitan Health Service Human Research Ethics
446 Committee, MURDOCH, Western Australia on 3rd September 2021 (ref: RGS0000004935) and 19th May
447 2022 (Ref: RGS0000005326), from St John of God Health Care Human Research Ethics Committee (ref:
448 1870) on 13th October 2021, and West Australian Aboriginal Health Ethics Committee (ref: HREC1146) on
449 29th April 2022. In New Zealand, the approval was obtained from Health and Disability Ethics Committees,
450 Wellington, New Zealand on 12 October 2021 (ref: 21/STH/213). Written informed consent will be
451 obtained from all participants. The results will be published in peer reviewed journals and presented at
452 scientific conferences to inform stakeholders. Study newsletters and lay summaries on webpages will be
453 used to disseminate the findings to patients.

454

455 Acknowledgements

456 We wish to thank all patients, family members, and staff members from all the participating sites for
457 their involvement in this study.

458

459

460 References:

- 461 1. NICOR | Adult Cardiac Surgery (Surgery Audit) [Internet]. [cited 2023 Dec 13]. Available from:
462 <https://www.nicor.org.uk/adult-cardiac-surgery-surgery-audit/>

- 463 2. About The Database | ANZSCTS [Internet]. [cited 2023 Dec 13]. Available from:
464 <https://anzscts.org/database/about/>
- 465 3. Ball L, Costantino F, Pelosi P. Postoperative complications of patients undergoing cardiac surgery.
466 *Curr Opin Crit Care* [Internet]. 2016 Aug 1 [cited 2023 Dec 13];22(4):386–92. Available from:
467 [https://journals.lww.com/co-](https://journals.lww.com/co-criticalcare/fulltext/2016/08000/postoperative_complications_of_patients_undergoing.18.aspx)
468 [criticalcare/fulltext/2016/08000/postoperative_complications_of_patients_undergoing.18.aspx](https://journals.lww.com/co-criticalcare/fulltext/2016/08000/postoperative_complications_of_patients_undergoing.18.aspx)
- 469 4. Snowdon D, Haines TP, Skinner EH. Preoperative intervention reduces postoperative pulmonary
470 complications but not length of stay in cardiac surgical patients: a systematic review. *J*
471 *Physiother*. 2014 Jun 1;60(2):66–77.
- 472 5. Westerlind A, Nilsson F, Ricksten SE. The use of continuous positive airway pressure by face mask
473 and thoracic epidural analgesia after lung transplantation. Gothenburg Lung Transplant Group. *J*
474 *Cardiothorac Vasc Anesth* [Internet]. 1999 [cited 2022 May 4];13(3):249–52. Available from:
475 <https://pubmed.ncbi.nlm.nih.gov/10392672/>
- 476 6. Gümüř F, Polat A, Yektař A, Erentuę V, Alagöl A. Readmission To Intensive Care Unit After
477 Coronary Bypass Operations in the Short Term. *Turk J Anaesthesiol Reanim* [Internet]. 2014 [cited
478 2022 May 4];42(4):162. Available from: [/pmc/articles/PMC4894143/](https://pubmed.ncbi.nlm.nih.gov/24894143/)
- 479 7. Bardell T, Legare JF, Buth KJ, Hirsch GM, Ali IS. ICU readmission after cardiac surgery. *European*
480 *Journal of Cardio-Thoracic Surgery* [Internet]. 2003 Mar 1 [cited 2023 Dec 13];23(3):354–9.
481 Available from: [https://dx.doi.org/10.1016/s1010-7940\(02\)00767-4](https://dx.doi.org/10.1016/s1010-7940(02)00767-4)
- 482 8. Jabbari A, Alijanpour E, Tabasi S. Clinical Usage of High-flow Oxygenation in Postcardiac Surgery
483 Patients. *Ann Card Anaesth* [Internet]. 2019 Jan 1 [cited 2023 Dec 13];22(1):107. Available from:
484 [/pmc/articles/PMC6350429/](https://pubmed.ncbi.nlm.nih.gov/3150429/)
- 485 9. Maggiore SM, Battilana M, Serano L, Petrini F. Ventilatory support after extubation in critically ill
486 patients. *Lancet Respir Med*. 2018 Dec 1;6(12):948–62.
- 487 10. Lu Z, Chang W, Meng S, Xue M, Xie J, Xu J, et al. The Effect of High-Flow Nasal Oxygen Therapy on
488 Postoperative Pulmonary Complications and Hospital Length of Stay in Postoperative Patients: A
489 Systematic Review and Meta-Analysis. *J Intensive Care Med* [Internet]. 2020 Oct 1 [cited 2022
490 Sep 4];35(10):1129–40. Available from:
491 <https://journals.sagepub.com/doi/full/10.1177/0885066618817718>
- 492 11. Wu X, Cao W, Zhang B, Wang S. Effect of high-flow nasal cannula oxygen therapy vs conventional
493 oxygen therapy on adult postcardiothoracic operation: A meta-analysis. *Medicine* [Internet].
494 2018 Oct 1 [cited 2022 Sep 4];97(41). Available from: [/pmc/articles/PMC6203525/](https://pubmed.ncbi.nlm.nih.gov/303525/)
- 495 12. Eaton Turner E, Jenks M. Cost-effectiveness analysis of the use of high-flow oxygen through nasal
496 cannula in intensive care units in NHS England. *Expert Rev Pharmacoecon Outcomes Res*
497 [Internet]. 2017 Dec 5 [cited 2022 Sep 5];18(3):331–7. Available from:
498 <https://europepmc.org/article/med/29187008>
- 499 13. Groessl EJ, Tally SR, Hillery N. Cost-Effectiveness of Humidified High-Flow Therapy (HHFT) for
500 COPD Patients on Long-Term Oxygen Therapy. *ClinicoEconomics and Outcomes Research*

- 501 [Internet]. 2023 Apr 5 [cited 2023 Jun 29];15:239–50. Available from:
502 [https://www.dovepress.com/cost-effectiveness-of-humidified-high-flow-therapy-hhft-for-copd-](https://www.dovepress.com/cost-effectiveness-of-humidified-high-flow-therapy-hhft-for-copd-patie-peer-reviewed-fulltext-article-CEOR)
503 [patie-peer-reviewed-fulltext-article-CEOR](https://www.dovepress.com/cost-effectiveness-of-humidified-high-flow-therapy-hhft-for-copd-patie-peer-reviewed-fulltext-article-CEOR)
- 504 14. Sørensen SS, Storgaard LH, Weinreich UM. Cost-Effectiveness of Domiciliary High Flow Nasal
505 Cannula Treatment in COPD Patients with Chronic Respiratory Failure. *Clinicoecon Outcomes Res*
506 [Internet]. 2021 [cited 2022 Sep 5];13:553–64. Available from:
507 <https://pubmed.ncbi.nlm.nih.gov/34168472/>
- 508 15. Fleeman N, Mahon J, Bates V, Dickson R, Dundar Y, Dwan K, et al. The clinical effectiveness and
509 cost-effectiveness of heated humidified high-flow nasal cannula compared with usual care for
510 preterm infants: systematic review and economic evaluation. *Health Technol Assess (Rockv)*.
511 2016 Apr 25;20(30):1–68.
- 512 16. Buendía JA, Acuña-Cordero R, Rodriguez-Martinez CE. The cost-utility of early use of high-flow
513 nasal cannula in bronchiolitis. *Health Econ Rev* [Internet]. 2021 Dec 1 [cited 2022 Oct
514 29];11(1):1–8. Available from:
515 <https://healtheconomicsreview.biomedcentral.com/articles/10.1186/s13561-021-00339-7>
- 516 17. Earwaker M, Villar S, Fox-Rushby J, Duckworth M, Dawson S, Steele J, et al. Effect of high-flow
517 nasal therapy on patient-centred outcomes in patients at high risk of postoperative pulmonary
518 complications after cardiac surgery: a study protocol for a multicentre adaptive randomised
519 controlled trial. *Trials* [Internet]. 2022 Dec 1 [cited 2023 Dec 14];23(1):1–18. Available from:
520 <https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-022-06180-5>
- 521 18. Dawson SN, Chiu Y Da, Klein AA, Earwaker M, Villar SS. Effect of high-flow nasal therapy on
522 patient-centred outcomes in patients at high risk of postoperative pulmonary complications after
523 cardiac surgery: a statistical analysis plan for NOTACS, a multicentre adaptive randomised
524 controlled trial. *Trials* [Internet]. 2022 Dec 1 [cited 2023 Dec 14];23(1):1–8. Available from:
525 <https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-022-06607-z>
- 526 19. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013
527 statement: Defining standard protocol items for clinical trials. *Ann Intern Med* [Internet]. 2013
528 Feb 5 [cited 2024 Sep 18];158(3):200–7. Available from: www.annals.org
- 529 20. 4 Economic evaluation | NICE health technology evaluations: the manual | Guidance | NICE.
- 530 21. PBAC Guidelines | 3A.1 Overview and rationale of the economic evaluation [Internet]. [cited
531 2023 Dec 15]. Available from: [https://pbac.pbs.gov.au/section-3a/3a-1-overview-and-rationale-](https://pbac.pbs.gov.au/section-3a/3a-1-overview-and-rationale-of-economic-evaluation.html)
532 [of-economic-evaluation.html](https://pbac.pbs.gov.au/section-3a/3a-1-overview-and-rationale-of-economic-evaluation.html)
- 533 22. Economic analysis - Pharmac | New Zealand Government [Internet]. [cited 2023 Dec 15].
534 Available from: [https://pharmac.govt.nz/medicine-funding-and-supply/the-funding-](https://pharmac.govt.nz/medicine-funding-and-supply/the-funding-process/policies-manuals-and-processes/economic-analysis)
535 [process/policies-manuals-and-processes/economic-analysis](https://pharmac.govt.nz/medicine-funding-and-supply/the-funding-process/policies-manuals-and-processes/economic-analysis)
- 536 23. Ramsey SD, Willke RJ, Glick H, Reed SD, Augustovski F, Jonsson B, et al. Cost-Effectiveness
537 Analysis Alongside Clinical Trials II—An ISPOR Good Research Practices Task Force Report. *Value*
538 *in Health* [Internet]. 2015 Mar 1 [cited 2023 Dec 21];18(2):161–72. Available from:
539 <http://www.valueinhealthjournal.com/article/S1098301515000169/fulltext>

- 540 24. AIRVO 2 High--Flow Standard Operating Procedure Paediatric Intensive Care Unit (PICU) Royal
541 Hospital for Children Glasgow.
- 542 25. Airvo™ 2 Nasal High Flow/HFNC System [2 - 60 L/min] | Fisher & Paykel Healthcare [Internet].
543 [cited 2023 Dec 15]. Available from: [https://www.fphcare.com/en-gb/hospital/adult-](https://www.fphcare.com/en-gb/hospital/adult-respiratory/optiflow/airvo-2-system/)
544 [respiratory/optiflow/airvo-2-system/](https://www.fphcare.com/en-gb/hospital/adult-respiratory/optiflow/airvo-2-system/)
- 545 26. NHS England » National Cost Collection for the NHS [Internet]. [cited 2022 Oct 3]. Available from:
546 <https://www.england.nhs.uk/costing-in-the-nhs/national-cost-collection/>
- 547 27. Pharmaceutical Benefits Scheme (PBS) | Home [Internet]. [cited 2024 Jun 28]. Available from:
548 <https://www.pbs.gov.au/pbs/home>
- 549 28. National Hospital Cost Data Collection | IHACPA [Internet]. [cited 2024 Jun 28]. Available from:
550 <https://www.ihacpa.gov.au/health-care/costing/national-hospital-cost-data-collection>
- 551 29. Cost Resource Manual - Pharmac | Te Pātaka Whaioranga | NZ Government [Internet]. [cited
552 2024 Jun 28]. Available from: [https://pharmac.govt.nz/medicine-funding-and-supply/the-](https://pharmac.govt.nz/medicine-funding-and-supply/the-funding-process/policies-manuals-and-processes/economic-analysis/cost-resource-manual)
553 [funding-process/policies-manuals-and-processes/economic-analysis/cost-resource-manual](https://pharmac.govt.nz/medicine-funding-and-supply/the-funding-process/policies-manuals-and-processes/economic-analysis/cost-resource-manual)
- 554 30. Average weekly earnings in Great Britain - Office for National Statistics [Internet]. [cited 2024 Jun
555 28]. Available from:
556 [https://www.ons.gov.uk/employmentandlabourmarket/peopleinwork/employmentandemploye](https://www.ons.gov.uk/employmentandlabourmarket/peopleinwork/employmentandemployeetypes/bulletins/averageweeklyearningsingreatbritain/april2024)
557 [etypes/bulletins/averageweeklyearningsingreatbritain/april2024](https://www.ons.gov.uk/employmentandlabourmarket/peopleinwork/employmentandemployeetypes/bulletins/averageweeklyearningsingreatbritain/april2024)
- 558 31. Unit Costs of Health and Social Care programme (2022 – 2027) | The new home for the Unit
559 Costs of Health and Social Care report [Internet]. [cited 2024 Jun 17]. Available from:
560 <https://www.pssru.ac.uk/unitcostsreport/>
- 561 32. MBS Online - MBS Online [Internet]. [cited 2024 Aug 8]. Available from:
562 <https://www.mbsonline.gov.au/>
- 563 33. nhs cost inflation index - Google Search [Internet]. [cited 2022 Oct 29]. Available from:
564 [https://www.google.com/search?q=nhs+cost+inflation+index&rlz=1C1GCEV_enGB992GB993&oq](https://www.google.com/search?q=nhs+cost+inflation+index&rlz=1C1GCEV_enGB992GB993&oq=NHS+cost+inflation+&aqs=chrome.0.0i512l2j69i57j0i512j0i390.3778j0j7&sourceid=chrome&ie=UTF-8)
565 [=NHS+cost+inflation+&aqs=chrome.0.0i512l2j69i57j0i512j0i390.3778j0j7&sourceid=chrome&ie=](https://www.google.com/search?q=nhs+cost+inflation+index&rlz=1C1GCEV_enGB992GB993&oq=NHS+cost+inflation+&aqs=chrome.0.0i512l2j69i57j0i512j0i390.3778j0j7&sourceid=chrome&ie=UTF-8)
566 [UTF-8](https://www.google.com/search?q=nhs+cost+inflation+index&rlz=1C1GCEV_enGB992GB993&oq=NHS+cost+inflation+&aqs=chrome.0.0i512l2j69i57j0i512j0i390.3778j0j7&sourceid=chrome&ie=UTF-8)
- 567 34. Appendix A: Use of GDP deflator - NHS Digital [Internet]. [cited 2022 Oct 29]. Available from:
568 [https://digital.nhs.uk/data-and-information/publications/statistical/adult-social-care-activity-](https://digital.nhs.uk/data-and-information/publications/statistical/adult-social-care-activity-and-finance-report/2020-21/appendix-a)
569 [and-finance-report/2020-21/appendix-a](https://digital.nhs.uk/data-and-information/publications/statistical/adult-social-care-activity-and-finance-report/2020-21/appendix-a)
- 570 35. Consumers price index (CPI) | Stats NZ [Internet]. [cited 2024 Jun 28]. Available from:
571 <https://www.stats.govt.nz/indicators/consumers-price-index-cpi/>
- 572 36. Consumer Price Index, Australia, March Quarter 2024 | Australian Bureau of Statistics [Internet].
573 [cited 2024 Jun 28]. Available from: [https://www.abs.gov.au/statistics/economy/price-indexes-](https://www.abs.gov.au/statistics/economy/price-indexes-and-inflation/consumer-price-index-australia/latest-release)
574 [and-inflation/consumer-price-index-australia/latest-release](https://www.abs.gov.au/statistics/economy/price-indexes-and-inflation/consumer-price-index-australia/latest-release)
- 575 37. 8 Discounting - Pharmac | New Zealand Government [Internet]. [cited 2023 Nov 24]. Available
576 from: <https://pharmac.govt.nz/medicine-funding-and-supply/the-funding-process/policies->

- 577 manuals-and-processes/economic-analysis/prescription-for-pharmacoeconomic-analysis-
578 methods-for-cost-utility-analysis/8-discounting/
- 579 38. Home - Office for National Statistics [Internet]. [cited 2023 Aug 23]. Available from:
580 <https://www.ons.gov.uk/>
- 581 39. Australian Bureau of Statistics [Internet]. [cited 2023 Aug 23]. Available from:
582 <https://www.abs.gov.au/>
- 583 40. Home | Stats NZ [Internet]. [cited 2023 Aug 23]. Available from: <https://www.stats.govt.nz/>
- 584 41. Myles PS, Shulman MA, Heritier S, Wallace S, McIlroy DR, McCluskey S, et al. Validation of days at
585 home as an outcome measure after surgery: a prospective cohort study in Australia. *BMJ Open*
586 [Internet]. 2017 Aug 1 [cited 2023 Jul 1];7(8). Available from:
587 <https://pubmed.ncbi.nlm.nih.gov/28821518/>
- 588 42. Bell M, Eriksson LI, Svensson T, Hallqvist L, Granath F, Reilly J, et al. Days at Home after Surgery:
589 An Integrated and Efficient Outcome Measure for Clinical Trials and Quality Assurance.
590 *EClinicalMedicine* [Internet]. 2019 May 1 [cited 2023 Jul 1];11:18–26. Available from:
591 <https://pubmed.ncbi.nlm.nih.gov/31317130/>
- 592 43. Snowden C, Swart M. Anaesthesia and Perioperative Medicine GIRFT Programme National
593 Specialty Report. 2021;
- 594 44. FAQs – EQ-5D [Internet]. [cited 2022 Nov 16]. Available from: [https://euroqol.org/eq-5d-
595 instruments/eq-5d-5l-about/faqs/](https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/faqs/)
- 596 45. O’Hagan A, Stevens JW. A framework for cost-effectiveness analysis from clinical trial data.
597 *Health Econ* [Internet]. 2001 Jun 1 [cited 2024 Jul 19];10(4):303–15. Available from:
598 <https://onlinelibrary.wiley.com/doi/full/10.1002/hec.617>
- 599 46. Howdon D, Rice N. Health care expenditures, age, proximity to death and morbidity: Implications
600 for an ageing population. *J Health Econ*. 2018 Jan 1;57:60–74.
- 601 47. Hazra NC, Rudisill C, Gulliford MC. Determinants of health care costs in the senior elderly: age,
602 comorbidity, impairment, or proximity to death? *European Journal of Health Economics*
603 [Internet]. 2018 Jul 1 [cited 2024 Jul 19];19(6):831–42. Available from:
604 <https://link.springer.com/article/10.1007/s10198-017-0926-2>
- 605 48. Van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for
606 the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L value sets. *Value in Health* [Internet]. 2012 Jul
607 1 [cited 2022 Oct 29];15(5):708–15. Available from:
608 <http://www.valueinhealthjournal.com/article/S1098301512000587/fulltext>
- 609 49. Norman R, Mulhern B, Lancsar E, Lorgelly P, Ratcliffe J, Street D, et al. The Use of a Discrete
610 Choice Experiment Including Both Duration and Dead for the Development of an EQ-5D-5L Value
611 Set for Australia. *Pharmacoeconomics* [Internet]. 2023 Apr 1 [cited 2023 Aug 23];41(4):427–38.
612 Available from: <https://link.springer.com/article/10.1007/s40273-023-01243-0>

- 613 50. Sullivan T, Hansen P, Ombler F, Derrett S, Devlin N. A new tool for creating personal and social
614 EQ-5D-5L value sets, including valuing 'dead.' *Soc Sci Med*. 2020 Feb 1;246:112707.
- 615 51. Position statement on use of the EQ-5D-5L value set for England (updated October 2019) |
616 Technology appraisal guidance | NICE guidance | Our programmes | What we do | About | NICE.
617 [cited 2022 Oct 29]; Available from: [https://www.nice.org.uk/about/what-we-do/our-](https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l)
618 [programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l](https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l)
- 619 52. Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. *Br Med Bull*
620 [Internet]. 2010 Dec 1 [cited 2024 Jun 18];96(1):5–21. Available from:
621 <https://dx.doi.org/10.1093/bmb/ldq033>
- 622 53. Linear interpolation - Wikipedia [Internet]. [cited 2024 Jun 18]. Available from:
623 [https://en.wikipedia.org/wiki/Linear_interpolation#Linear_interpolation_between_two_known_](https://en.wikipedia.org/wiki/Linear_interpolation#Linear_interpolation_between_two_known_points)
624 [points](https://en.wikipedia.org/wiki/Linear_interpolation#Linear_interpolation_between_two_known_points)
- 625 54. Faria R, Gomes M, Epstein D, White IR. A Guide to Handling Missing Data in Cost-Effectiveness
626 Analysis Conducted Within Randomised Controlled Trials. *Pharmacoeconomics* [Internet]. 2014
627 Nov 26 [cited 2023 Jul 2];32(12):1157–70. Available from:
628 <https://link.springer.com/article/10.1007/s40273-014-0193-3>
- 629 55. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and
630 guidance for practice. *Stat Med* [Internet]. 2011 Feb 20 [cited 2023 Jul 2];30(4):377–99. Available
631 from: <https://pubmed.ncbi.nlm.nih.gov/21225900/>
- 632 56. Leurent B, Gomes M, Cro S, Wiles N, Carpenter JR. Reference-based multiple imputation for
633 missing data sensitivity analyses in trial-based cost-effectiveness analysis. *Health Econ* [Internet].
634 2020 Feb 1 [cited 2024 Jul 19];29(2):171–84. Available from:
635 <https://onlinelibrary.wiley.com/doi/full/10.1002/hec.3963>
- 636 57. Devlin N, Parkin D, Janssen B. Methods for Analysing and Reporting EQ-5D Data. *Methods for*
637 *Analysing and Reporting EQ-5D Data*. 2020;
- 638 58. Willan AR, Lin DY, Manca A. Regression methods for cost-effectiveness analysis with censored
639 data. *Stat Med* [Internet]. 2005 Jan 15 [cited 2023 Jul 3];24(1):131–45. Available from:
640 <https://pubmed.ncbi.nlm.nih.gov/15515137/>
- 641 59. Edney LC, Haji Ali Afzali H, Cheng TC, Karnon J. Estimating the Reference Incremental Cost-
642 Effectiveness Ratio for the Australian Health System. *Pharmacoeconomics* [Internet]. 2018 Feb 1
643 [cited 2023 Aug 23];36(2):239–52. Available from: <https://pubmed.ncbi.nlm.nih.gov/29273843/>
- 644 60. Kvzhinadze G, Wilson N, Nair N, McLeod M, Blakely T. How much might a society spend on life-
645 saving interventions at different ages while remaining cost-effective? A case study in a country
646 with detailed data. *Popul Health Metr* [Internet]. 2015 Jul 8 [cited 2023 Aug 23];13(1):1–5.
647 Available from: [/pmc/articles/PMC4493819/](https://pubmed.ncbi.nlm.nih.gov/264493819/)
- 648 61. Drummond M, Barbieri M, Cook J, Glick HA, Lis J, Malik F, et al. Transferability of Economic
649 Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force Report. *Value in*
650 *Health*. 2009 Jun 1;12(4):409–18.

- 651 62. Manca A, Willan AR. “Lost in translation”: Accounting for between-country differences in the
652 analysis of multinational cost-effectiveness data. *Pharmacoeconomics* [Internet]. 2006 Nov 25
653 [cited 2023 Jun 26];24(11):1101–19. Available from:
654 <https://link.springer.com/article/10.2165/00019053-200624110-00007>
- 655 63. Gail M, Simon R. Testing for Qualitative Interactions between Treatment Effects and Patient
656 Subsets. *Biometrics*. 1985 Jun;41(2):361.
- 657 64. Cook JR, Drummond M, Glick H, Heyse JF. Assessing the appropriateness of combining economic
658 data from multinational clinical trials. *Stat Med*. 2003 Jun 30;22(12):1955–76.
- 659 65. Piantadosi S, Gail MH. A comparison of the power of two tests for qualitative interactions. *Stat*
660 *Med* [Internet]. 1993 Jan 1 [cited 2023 Jul 3];12(13):1239–48. Available from:
661 <https://onlinelibrary.wiley.com/doi/full/10.1002/sim.4780121305>
- 662 66. Manca A, Lambert PC, Sculpher M, Rice N. Cost-Effectiveness Analysis Using Data from
663 Multinational Trials: The Use of Bivariate Hierarchical Modeling.
664 <http://dx.doi.org/10.1177/0272989X07302132> [Internet]. 2007 Jul 1 [cited 2024 Aug
665 14];27(4):471–90. Available from:
666 <https://journals.sagepub.com/doi/10.1177/0272989X07302132>
- 667 67. Zochios V, Collier T, Blandszun G, Butchart A, Earwaker M, Jones N, et al. The effect of high-flow
668 nasal oxygen on hospital length of stay in cardiac surgical patients at high risk for respiratory
669 complications: a randomised controlled trial. *Anaesthesia* [Internet]. 2018 Dec 1 [cited 2022 Oct
670 3];73(12):1478–88. Available from: <https://pubmed.ncbi.nlm.nih.gov/30019747/>
- 671 68. Prescription for Pharmacoeconomic Analysis - Pharmac | New Zealand Government [Internet].
672 [cited 2024 May 25]. Available from: <https://pharmac.govt.nz/medicine-funding-and-supply/the-funding-process/policies-manuals-and-processes/economic-analysis/prescription-for-pharmacoeconomic-analysis-methods-for-cost-utility-analysis>
- 673
674
- 675 69. PBAC Guidelines | Section 3A Cost-effectiveness analysis [Internet]. [cited 2024 May 25].
676 Available from: <https://pbac.pbs.gov.au/section-3a-cost-effectiveness-analysis.html>
- 677

678 Supporting information

679 **S1 file. S1 Appendix**

680 **S2 file. S2 Appendix**

| | Study Period | | | | | |
|---|---|-------------------|---|------------------|----------------------------|----------------------------|
| | Enrolment | | Allocation | Post-allocation | | Close-out |
| | Screening | Baseline | Randomization | Discharge | 30 Days (+30 days) post-op | 90 Days (+90 days) post-op |
| Timepoint** | Prior to Surgical Admission (or after admission if in-house urgent) | Surgery Admission | During or After surgery & prior to extubation | Day of Discharge | 30 days (+30 days) post-op | 90 days (+90 days) post-op |
| Enrolment | | | | | | |
| Inclusion/Exclusion Criteria | X | | | | | |
| Informed Consent | | X | | | | |
| Demographics | | X | | | | |
| Past Medical History | | X | | | | |
| EuroSCORE II & ARISCAT | | X | | | | |
| Risk Assessments | | | | | | |
| It is made available under a CC-BY 4.0 International license . | | | | | | |
| Interventions | | | | | | |
| Initiation of high flow nasal therapy | | | X | | | |
| Initiation of standard oxygen therapy | | | X | | | |
| Assessments | | | | | | |
| EQ-5D-5L & Barthel Questionnaires | | X | | X | X | X |
| Participant & Family Resource Use Questionnaires | | X | | X | X | X |
| Adverse & Serious Adverse Events Assessed (from the point of extubation) | | | X-----X | | | |
| Inpatient Medication Log (to start from the point of extubation) | | | X-----X | | | |
| Inpatient Location Log (to start from the point of extubation) | | | X-----X | | | |
| Inpatient Oxygen Therapy Log (to start from the point of extubation) | | | X-----X | | | |
| Participant Location and Medication Diary | | | | X-----X | | |
| ROX Index | | | X-----X | | | |
| Record of Respiratory Support Escalation | | | X-----X | | | |
| Record of Post-operative Complications | | | X-----X | | | |
| Record of Intensive care Length of stay and Re-admissions | | | | X | | |
| Record of Hospital Discharge Destination | | | | X | | |
| Record of Hospital Length of Stay | | | | X | | |

Figure 1